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In 1974, 14 years after the advent of regular maintenance haemodialysis, Linder and 
colleagues first reported the powerful relationship between end-stage renal failure and 
cardiovascular complications.1 This is now generally recognised, and the statistics 
quantifying this excess risk - such as the 100-fold increase in cardiovascular mortality 
associated with a requirement for chronic dialysis below the age of 45 years - are 
frequently quoted. More recently, however, clinicians have become more aware of the 
association between milder degrees of renal dysfunction and cardiac morbidity and 
mortality.  
 
There are several reasons for an increased interest in the relationship between kidney 
and cardiovascular disease. An ageing population with an increased prevalence of 
obesity, hypertension and diabetes has resulted in rising levels of chronic renal 
disease. Among 6,233 participants in the Framingham Heart Study, 8% had mild renal 
insufficiency based on measures of serum creatinine.2 Likewise, the third National 
Health and Nutrition Examination Survey estimated that, in the United States, almost 
10% of men and 2% of women have creatinine levels of 1.5mg/dL (~133µmol/L) or 
greater.3
 
The association between renal impairment and cardiovascular outcome has also been 
emphasised in recent reports by several authoritative working groups. These, 
combined with several large cohort studies, have highlighted the problem and 
confirmed the importance of renal dysfunction in multiple patient populations. 
 
Another factor may be the increasing utilisation of more precise estimates of renal 
function. In particular, the Modification of Diet in Renal Disease formula allows 
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estimation of glomerular filtration rate (GFR) on the basis of a patient's age, serum 
creatinine, gender and racial background - facilitating its use in everyday clinical 
practice. If the estimated GFR is used many more individuals will be identified as 
having chronic renal insufficiency. For example, in this issue of the Journal, 
Holzmann and colleagues demonstrate that, in a cohort of 6,575 patients undergoing 
isolated first coronary artery bypass grafting (CABG), 21% would be identified as 
having chronic kidney disease on the basis of an estimated GFR <60mL/min/1.73m2. 
Only 6% of patients would have been identified as having renal dysfunction using the 
commonly accepted cut-off of creatinine >1.5mg/dL.4 Thus, the estimated GFR 
allows clinicians to make a much more precise estimate of kidney function - 
identifying subtle, but prognostically important, renal impairment. As one would 
expect, estimated GFR is, therefore, a better discriminator of risk than serum 
creatinine, and is now generally accepted as the preferred measure in this context. 
 
Renal dysfunction in patients undergoing myocardial revascularisation 
During myocardial revascularisation even mild degrees of renal dysfunction are 
increasingly recognised as a key prognostic indicator. Several studies have 
demonstrated that end-stage renal failure predicts a worse outcome from CABG. A 
poorer prognosis has also been described among patients with renal dysfunction not 
requiring dialysis. Most such studies have included patients with moderate to severe 
elevations of creatinine, dichotomised on the basis of largely arbitrary cut-off levels. 
Recently, several authors have demonstrated that milder degrees of renal impairment, 
identified using the estimated GFR, are also important determinants of outcome.5,6 
One such study is published in this issue of the Journal. As noted above, Holzmann 
and colleagues studied patients undergoing isolated first CABG at the Karolinska 
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Hospital, Stockholm between 1980 and 1995. Their principal finding was that, even 
after correction for confounding variables, the hazard of death and/or myocardial 
infarction increased as the estimated GFR fell: an association that was similar in both 
men and women.4 Interestingly, the percentage of patients with chronic kidney 
disease (<60mL/min/1.73m2) undergoing CABG between 1990 and 1995 (26%) was 
double that among those operated on between 1980 and 1984 (13%).4 Importantly, 
this study excluded an additional 136 patients who died within the initial 30-days of 
surgery, and does not assess the impact of renal function on early outcome after 
CABG. Other recent data confirm that estimated GFR is a very powerful, 
independent, predictor of early morbidity and mortality.5,6
 
Renal dysfunction is also an important determinant of outcome following 
percutaneous coronary intervention where, as in patients undergoing CABG, even 
mild impairment is associated with a considerable increase in 1-year mortality, 
independent of other factors.7 Studies in the 1990s suggested that patients with severe 
kidney disease treated with balloon angioplasty had a poor procedural outcome and 
high restenosis rates. More recent data suggest that in patients with milder degrees of 
renal dysfunction, treated predominantly with intra-coronary stents, rates of restenosis 
and acute myocardial infarction are no higher than those with normal renal function 
after an average follow-up of 9 months.8
 
Relationship between estimated GFR and outcome 
Holzmann and colleagues did not specifically address the pattern of the relationship 
between declining GFR and outcome. Their data are, however, in keeping with the 
observations of others that the risk is non-linear.5,6 A GFR of 90mL/min/1.73m2 or 
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above is regarded as normal. Patients at high-risk of, or with pre-existing, 
cardiovascular disease who have mild renal dysfunction (estimated GFR 60-
89mL/min/1.73m2) are at slightly increased risk of adverse events. There appears to 
be a threshold effect whereby risk increases greatly as the estimated GFR falls below 
60mL/min/1.73m2 – the level at which a patient is regarded as having ‘chronic kidney 
disease’ and at which the regulatory functions of the kidney begin to fail, with an 
associated increase in the prevalence of ‘renal-specific’ cardiovascular risk factors 
(see below). 
 
Mechanisms whereby pre-procedural renal function influences outcome from 
revascularisation 
The mechanisms whereby minor abnormalities in renal function mediate a worse 
outcome are complex. Renal function tends to decline with age and dysfunction is a 
consequence of several conventional cardiovascular risk factors, such as diabetes 
mellitus and hypertension. Likewise, impaired kidney function exacerbates the effects 
of these conditions, and in addition is associated with dyslipidaemia plus a variety of 
other less well-defined risk factors such as increased acute phase proteins, reduced 
antioxidants and hyperhomocysteinaemia. It has been suggested that reductions in 
haemoglobin and abnormalities of calcium/phosphate homeostatis might also be 
contributory and, although more pronounced in advanced renal disease, such changes 
can be observed in patients with relatively modest reductions in GFR.  
 
Renal dysfunction is a common consequence of reduced left ventricular systolic 
function and heart failure. This, most likely, reflects a combination of factors 
including the direct relationship between impaired haemodynamic status and renal 
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function, neurohormonal activation, effects of medications and the results of the 
underlying disease processes. Not only can left ventricular impairment result in 
reduced renal function, but the converse may also occur: chronic kidney disease is 
itself a risk factor for left ventricular hypertrophy, dilatation and dysfunction. 
 
In summary, therefore, the powerful prognostic utility of renal function is assumed in 
part to be due to its association with, and exacerbation of, established and suspected 
risk factors for accelerated atherosclerosis and left ventricular dysfunction. In 
addition, the kidney is particularly sensitive to the effects of generalised vascular 
dysfunction and haemodynamic disturbances– and may therefore serve as a useful 
‘barometer’ of cardiovascular health. Finally, there are extensive data demonstrating 
that patients with even mild renal impairment are less likely to receive therapies that 
can improve cardiac outcome. 
 
Effects of post-procedural renal function on outcome 
Relatively few studies have assessed the impact of post-operative renal function on 
long-term outcome. Those data that are available confirm that pre-operative renal 
impairment is a major predictor of peri-procedural deterioration and that, both after 
CABG and PCI, this is associated with a worse outcome.9,10 Indeed, in this setting, 
even relatively minor changes predict a higher mortality. The mechanisms underlying 
this are poorly defined but may include a decreased renal reserve (with increased 
susceptibility to the effects haemodynamic compromise), worse underlying cardiac 
disease, a higher prevalence of diabetes, increased age and poorer systolic function or 
clinical heart failure. In addition, renal dysfunction is a common consequence of 
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many other post-operative complications – such as sepsis – that in turn have profound 
implications for outcome. 
 
Clinical implications 
The data presented by Holzmann and colleagues add to the growing literature 
demonstrating that renal dysfunction, particularly when measured accurately using the 
estimated GFR, is a potent predictor of outcome following CABG. The underlying 
mechanisms are multifaceted and include both direct and indirect effects. It appears, 
however, that renal dysfunction can be regarded both as a marker and a mediator of 
increased risk. 
 
Despite the impact of kidney disease on the outcome from CABG, current risk-
prediction models in cardiac surgery either exclude renal function altogether, or rely 
on serum creatinine used as a dichotomous variable, the need for renal replacement 
therapy or poorly-defined criteria such as ‘renal failure’. Further work is required to 
assess whether the inclusion of more discriminatory measures of renal function might 
result in improved pre-operative risk stratification. Increased use of the estimated 
GFR would also increase the recognition of otherwise unapparent renal dysfunction 
and, hopefully, encourage the use of therapies already proven to improve 
cardiovascular outcome. Ultimately, prospective studies are required to devise 
strategies that reduce the risk associated with renal dysfunction in this setting. 
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